Correction to: Biologic Drug Quality Assurance to Optimize HER2+  Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3
The article Biologic Drug Quality Assurance to Optimize HER2+  Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3, (Source: Targeted Oncology)
Source: Targeted Oncology - October 20, 2020 Category: Cancer & Oncology Source Type: research
Targeting Nuclear Export Proteins in Multiple Myeloma Therapy
AbstractMultiple myeloma (MM) is an incurable malignancy of plasma cells with a clinical course characterized by multiple relapses and treatment refractoriness. While recent treatment advancements have extended overall survival (OS), refractory MM has a poor prognosis, with a median OS of between 4 and 6 months. Nuclear export inhibition, specifically inhibition of CRM1/XPO1, is an emerging novel treatment modality that has shown promise in treatment-refractory MM. Initially discovered in yeast in 1983, early clinical applications were met with significant toxicities that limited their utility. The creation of small molecu...
Source: Targeted Oncology - October 19, 2020 Category: Cancer & Oncology Source Type: research
Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry
ConclusionsAnti-EGFR rechallenge provides clinical benefit in patients withRAS wild-type metastatic CRC. (Source: Targeted Oncology)
Source: Targeted Oncology - October 17, 2020 Category: Cancer & Oncology Source Type: research
Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT - 3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
ConclusionsMonotherapy with sunitinib does not have clinical activity in patients with mCRC withFLT-3 amplification and should not be prescribed for off-label use. Other treatments should be considered for these patients, including treatments offered in clinical trials.Clinical Trial registrationNCT02693535 (26 February 2016). (Source: Targeted Oncology)
Source: Targeted Oncology - October 17, 2020 Category: Cancer & Oncology Source Type: research
Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data
AbstractGenomic instability is one of the hallmarks of cancer. The incidence of genetic alterations in homologous recombination repair genes increases during cancer progression, and 20% of prostate cancers (PCas) have defects in DNA repair genes. Several somatic and germline gene alterations drive prostate cancer tumorigenesis, and the most important of these areBRCA2,BRCA1,ATM andCHEK2. There is a group of BRCAness tumours that share phenotypic and genotypic properties with classicalBRCA-mutated tumours. Poly(ADP-ribose) polymerase inhibitors (PARPis) show synthetic lethality in cancer cells with impaired homologous recom...
Source: Targeted Oncology - October 12, 2020 Category: Cancer & Oncology Source Type: research
